A MULTICENTER PHASE 1B/2 STUDY OF NEOADJUVANT PEMBROLIZUMAB AND CISPLATIN CHEMOTHERAPY FOR MUSCLE INVASIVE UROTHELIAL CANCER

Authors

Publication/Presentation Date

4-2019

Volume

201

Issue

4

First Page

924

Last Page

925

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Department of Surgery

Document Type

Article

Share

COinS